Clinical analysis of autologous hematopoietic stem cell transplantation in the treatment of advanced/recurrent nasal type extranodal NK/T-cell lymphoma.
10.3760/cma.j.issn.0253-2727.2018.07.008
- Author:
Fang Fang YUAN
1
;
Qing Song YIN
;
Yue Wen FU
;
Qian WANG
;
Lin CHEN
;
Rui Hua MI
;
Yu Fu LI
;
Xu Dong WEI
;
Yong Ping SONG
Author Information
1. Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
- Publication Type:Journal Article
- Keywords:
Antineoplastic combined chemotherapy protocols;
Autologous hematopoietic stem cell transplantation;
Lymphoma, extranodal NK-T-cell;
Treatment outcome
- MeSH:
Adolescent;
Adult;
Antineoplastic Combined Chemotherapy Protocols;
Asparaginase;
Female;
Hematopoietic Stem Cell Transplantation;
Humans;
Lymphoma, Extranodal NK-T-Cell;
Male;
Middle Aged;
Neoplasm Recurrence, Local;
Nose Neoplasms;
Transplantation, Autologous;
Young Adult
- From:
Chinese Journal of Hematology
2018;39(7):569-572
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the efficacy and safety of asparaginase based chemotherapy bridging autologous hematopoietic stem cell transplantation (auto-HSCT) in the treatment of 16 patients with nasal type extranodal NK/T-cell lymphoma (ENKTL). Methods: From January 2012 to June 2017, 16 patients with nasal type extranodal NK/T-cell lymphoma reached complete remission by L-asparaginase based regimens, and then received auto-HSCT. Results: ①Of the 16 patients, 12 were males and 4 females, with a median age of 35.5 (14-61) years. There were 11 patients in the first complete remission (CR1) and 5 in the second CR (CR2) before transplantation, respectively. EB virus (EBV) DNA (EBV-DNA) was negative and positive in 13 and 3 cases respectively before transplantation. ②Hematopoietic reconstitution was achieved in all 16 cases. The median time for neutrophils implantation was 12 (8-17) days, and that of platelet implantation was 15.5 (12-24) days. ③To the last follow-up, there were no transplant related deaths, 3 patients died of disease progression. The median overall survival (OS) time and progression-free survival time (PFS) were not reached. Seven patients lived with no disease progression more than 2 years. ④The OS and PFS of patients at CR(1) before auto-HSCT are better than that of patients at CR(2), but there was no statistically significant difference (P=0.162, P=0.123). There was no significant difference in OS and PFS between EBV-DNA negative and positive patients before transplantation (P=0.280, P=0.244). Conclusions: L-asparaginase based regimens bridging auto-HSCT is a safe and highly effective for advanced-stage and relapsed ENKTL treatment.
